JP2021501202A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021501202A5 JP2021501202A5 JP2020543258A JP2020543258A JP2021501202A5 JP 2021501202 A5 JP2021501202 A5 JP 2021501202A5 JP 2020543258 A JP2020543258 A JP 2020543258A JP 2020543258 A JP2020543258 A JP 2020543258A JP 2021501202 A5 JP2021501202 A5 JP 2021501202A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- alkyl
- compound
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 *c(cc1)c(*)cc1S(c(cc1)cc(*)c1N(C=NN1)C1=S)(=O)=O Chemical compound *c(cc1)c(*)cc1S(c(cc1)cc(*)c1N(C=NN1)C1=S)(=O)=O 0.000 description 6
- BJWHWZOMLHXKPF-UHFFFAOYSA-N O=S(c(cc1)ccc1N(C=NN1)C1=S)(c(cc1)cc(C(F)(F)F)c1Cl)=O Chemical compound O=S(c(cc1)ccc1N(C=NN1)C1=S)(c(cc1)cc(C(F)(F)F)c1Cl)=O BJWHWZOMLHXKPF-UHFFFAOYSA-N 0.000 description 4
- LVSRXKVDSYTMNS-UHFFFAOYSA-N O=S(c(cc1C(F)(F)F)ccc1Cl)(c(cc1N2CCOCC2)ccc1N(C=NN1)C1=S)=O Chemical compound O=S(c(cc1C(F)(F)F)ccc1Cl)(c(cc1N2CCOCC2)ccc1N(C=NN1)C1=S)=O LVSRXKVDSYTMNS-UHFFFAOYSA-N 0.000 description 4
- MLJOILDVPRGUBB-UHFFFAOYSA-N CC(C=CC(C1)S(c(cc2)ccc2N(C=NN2)C2=S)(=O)=O)=C1C(F)(F)F Chemical compound CC(C=CC(C1)S(c(cc2)ccc2N(C=NN2)C2=S)(=O)=O)=C1C(F)(F)F MLJOILDVPRGUBB-UHFFFAOYSA-N 0.000 description 2
- JGYMLRFLRKQKFK-UHFFFAOYSA-N CCOCCCOc1cc(S(c(cc2)cc(C(F)(F)F)c2Cl)(=O)=O)ccc1N(C=NN1)C1=S Chemical compound CCOCCCOc1cc(S(c(cc2)cc(C(F)(F)F)c2Cl)(=O)=O)ccc1N(C=NN1)C1=S JGYMLRFLRKQKFK-UHFFFAOYSA-N 0.000 description 2
- PFGRCDCBWOEEFM-UHFFFAOYSA-N CCOCCOC(C1)=CC=CC1S(c(cc1)ccc1N(C=NN1)C1=S)(=O)=O Chemical compound CCOCCOC(C1)=CC=CC1S(c(cc1)ccc1N(C=NN1)C1=S)(=O)=O PFGRCDCBWOEEFM-UHFFFAOYSA-N 0.000 description 2
- DDASGMSESIJHPI-UHFFFAOYSA-N CN(CC1)CCN1c1cc(S(c(cc2)cc(C(F)(F)F)c2Cl)(=O)=O)ccc1N(C=NN1)C1=S Chemical compound CN(CC1)CCN1c1cc(S(c(cc2)cc(C(F)(F)F)c2Cl)(=O)=O)ccc1N(C=NN1)C1=S DDASGMSESIJHPI-UHFFFAOYSA-N 0.000 description 2
- XGXYECKJJHUMNY-UHFFFAOYSA-N COCCOc1cccc(S(c(cc2)ccc2N(C=NN2)C2=S)(=O)=O)c1 Chemical compound COCCOc1cccc(S(c(cc2)ccc2N(C=NN2)C2=S)(=O)=O)c1 XGXYECKJJHUMNY-UHFFFAOYSA-N 0.000 description 2
- PWHDKJDNBVLTPG-UHFFFAOYSA-N COc(cc1)ccc1S(c(cc1)ccc1N(C=NN1)C1=S)(=O)=O Chemical compound COc(cc1)ccc1S(c(cc1)ccc1N(C=NN1)C1=S)(=O)=O PWHDKJDNBVLTPG-UHFFFAOYSA-N 0.000 description 2
- XDKARSCTAIMMMH-UHFFFAOYSA-N Cc(cc(cc1)S(Cc(cc2)ccc2N(C=NN2)C2=S)(=O)=O)c1Cl Chemical compound Cc(cc(cc1)S(Cc(cc2)ccc2N(C=NN2)C2=S)(=O)=O)c1Cl XDKARSCTAIMMMH-UHFFFAOYSA-N 0.000 description 2
- ZYYUGYKDUZBBPG-UHFFFAOYSA-N Cc(cc1)ccc1S(c(cc1)ccc1N(C=NN1)C1=S)(=O)=O Chemical compound Cc(cc1)ccc1S(c(cc1)ccc1N(C=NN1)C1=S)(=O)=O ZYYUGYKDUZBBPG-UHFFFAOYSA-N 0.000 description 2
- VVZLDBPRESTKMI-UHFFFAOYSA-N Cc1cccc(S(c(cc2)ccc2N(C=NN2)C2=S)(=O)=O)c1 Chemical compound Cc1cccc(S(c(cc2)ccc2N(C=NN2)C2=S)(=O)=O)c1 VVZLDBPRESTKMI-UHFFFAOYSA-N 0.000 description 2
- DYPHXJSMKFKFEV-UHFFFAOYSA-N N#Cc1cc(S(c(cc2)ccc2N(C=NN2)C2=S)(=O)=O)ccc1 Chemical compound N#Cc1cc(S(c(cc2)ccc2N(C=NN2)C2=S)(=O)=O)ccc1 DYPHXJSMKFKFEV-UHFFFAOYSA-N 0.000 description 2
- NVUMIZYTPVJJFQ-UHFFFAOYSA-N O=S(c(cc1)cc(C(F)(F)F)c1Cl)(c(cc1N2CCCC2)ccc1N(C=NN1)C1=S)=O Chemical compound O=S(c(cc1)cc(C(F)(F)F)c1Cl)(c(cc1N2CCCC2)ccc1N(C=NN1)C1=S)=O NVUMIZYTPVJJFQ-UHFFFAOYSA-N 0.000 description 2
- NBAWEYFXKDHXDB-UHFFFAOYSA-N O=S(c(cc1)ccc1N(C=NN1)C1=S)(c(cc1)ccc1N1CCOCC1)=O Chemical compound O=S(c(cc1)ccc1N(C=NN1)C1=S)(c(cc1)ccc1N1CCOCC1)=O NBAWEYFXKDHXDB-UHFFFAOYSA-N 0.000 description 2
- BKXODGURHNZWOJ-UHFFFAOYSA-N O=S(c1ccccc1)(c(cc1)ccc1N(C=NN1)C1=S)=O Chemical compound O=S(c1ccccc1)(c(cc1)ccc1N(C=NN1)C1=S)=O BKXODGURHNZWOJ-UHFFFAOYSA-N 0.000 description 2
- WQWQZKLHSMNXSN-UHFFFAOYSA-N OCCNc1cc(S(c(cc2)cc(C(F)(F)F)c2Cl)(=O)=O)ccc1N(C=NN1)C1=S Chemical compound OCCNc1cc(S(c(cc2)cc(C(F)(F)F)c2Cl)(=O)=O)ccc1N(C=NN1)C1=S WQWQZKLHSMNXSN-UHFFFAOYSA-N 0.000 description 2
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023076473A JP2023100842A (ja) | 2017-10-30 | 2023-05-08 | 置換フェニルスルホニルフェニルトリアゾールチオンおよびその使用法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762579070P | 2017-10-30 | 2017-10-30 | |
| US62/579,070 | 2017-10-30 | ||
| US201762584630P | 2017-11-10 | 2017-11-10 | |
| US62/584,630 | 2017-11-10 | ||
| PCT/US2018/058050 WO2019089478A1 (en) | 2017-10-30 | 2018-10-29 | Substituted phenyl sulfonyl phenyl triazole thiones and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023076473A Division JP2023100842A (ja) | 2017-10-30 | 2023-05-08 | 置換フェニルスルホニルフェニルトリアゾールチオンおよびその使用法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021501202A JP2021501202A (ja) | 2021-01-14 |
| JP2021501202A5 true JP2021501202A5 (https=) | 2021-11-18 |
| JP7277473B2 JP7277473B2 (ja) | 2023-05-19 |
Family
ID=66333645
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020543258A Active JP7277473B2 (ja) | 2017-10-30 | 2018-10-29 | 置換フェニルスルホニルフェニルトリアゾールチオンおよびその使用法 |
| JP2023076473A Pending JP2023100842A (ja) | 2017-10-30 | 2023-05-08 | 置換フェニルスルホニルフェニルトリアゾールチオンおよびその使用法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023076473A Pending JP2023100842A (ja) | 2017-10-30 | 2023-05-08 | 置換フェニルスルホニルフェニルトリアゾールチオンおよびその使用法 |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US10501423B2 (https=) |
| EP (1) | EP3703675A4 (https=) |
| JP (2) | JP7277473B2 (https=) |
| KR (1) | KR102639231B1 (https=) |
| CN (1) | CN111372579B (https=) |
| AU (1) | AU2018359224B2 (https=) |
| BR (1) | BR112020008727A2 (https=) |
| CA (1) | CA3080578A1 (https=) |
| IL (1) | IL274010B2 (https=) |
| MX (1) | MX2020004202A (https=) |
| SG (1) | SG11202003879RA (https=) |
| WO (1) | WO2019089478A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202003879RA (en) | 2017-10-30 | 2020-05-28 | Neuropore Therapies Inc | Substituted phenyl sulfonyl phenyl triazole thiones and uses thereof |
| WO2019246454A1 (en) * | 2018-06-20 | 2019-12-26 | Neuropore Therapies, Inc. | Method of treating a condition associated with neurodegeneration using inhibitors of oat3 |
| CN117384029B (zh) * | 2023-12-12 | 2024-02-20 | 山东国邦药业有限公司 | 一种2,4,5-三氟苯乙酸的合成方法 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1476503A (en) | 1973-06-21 | 1977-06-16 | Sterling Drug Inc | 1-arylamino-and 1-arylimino-pyrroles and preparation thereof |
| US4279637A (en) | 1979-06-02 | 1981-07-21 | Velsicol Chemical Corporation | Herbicidal N-substituted 4-imidazolin-2-ones |
| DE3307506A1 (de) | 1983-03-03 | 1984-09-06 | Agfa-Gevaert Ag, 5090 Leverkusen | Fotografisches aufzeichnungsmaterial mit inhibitorvorlaeuferverbindungen |
| US5108486A (en) * | 1990-02-09 | 1992-04-28 | Kanagawa Chemical Laboratory, Ltd. | Herbicidal substituted-phenyl-1,2,4-triazol-5(1H)-thiones and -ones |
| US20040110785A1 (en) | 2001-02-02 | 2004-06-10 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| DE10123586A1 (de) * | 2001-05-08 | 2002-11-28 | Schering Ag | 3,5-Diamino-1,2,4-triazole als Kinase Inhibitoren |
| US20020183306A1 (en) | 2001-05-30 | 2002-12-05 | Pfizer Inc. | Combination treatment for sleep disorders including sleep apnea |
| RU2223952C2 (ru) | 2001-06-04 | 2004-02-20 | Институт физиологически активных веществ РАН | Производные n,s-замещенных n'-1-[(гетеро)арил]-n'-[(гетеро)арил]метилизотиомочевин или их солей с фармакологически приемлемыми кислотами нх, способы получения их солей и оснований, фармацевтическая композиция, способ лечения и способ изучения глутаматэргической системы |
| EP2168576A3 (en) | 2001-09-14 | 2010-05-26 | Shionogi & Co., Ltd. | Tricyclic compounds for treating dyslipidemia and arteriosclerotic diseases |
| SE0301232D0 (sv) | 2003-04-25 | 2003-04-25 | Astrazeneca Ab | Novel use |
| MXPA06000269A (es) | 2003-07-09 | 2006-04-07 | Hoffmann La Roche | Tiofenilaminoimidazolinas. |
| DE10344223A1 (de) | 2003-09-24 | 2005-04-21 | Merck Patent Gmbh | 1,3-Benzoxazolylderivate als Kinase-Inhibitoren |
| US20050228031A1 (en) | 2004-04-13 | 2005-10-13 | Bilodeau Mark T | Tyrosine kinase inhibitors |
| US7008748B1 (en) * | 2004-09-07 | 2006-03-07 | Eastman Kodak Company | Silver salt-toner co-precipitates and imaging materials |
| US7429667B2 (en) | 2005-01-20 | 2008-09-30 | Ardea Biosciences, Inc. | Phenylamino isothiazole carboxamidines as MEK inhibitors |
| US20060217390A1 (en) | 2005-02-24 | 2006-09-28 | Esmir Gunic | Cycloalkl, aryl and heteroaryl amino isothiazoles for the treatment of Hepatitis C virus |
| UA92746C2 (en) | 2005-05-09 | 2010-12-10 | Акилайон Фармасьютикалз, Инк. | Thiazole compounds and methods of use |
| US20060276464A1 (en) | 2005-05-13 | 2006-12-07 | Wyeth | Diarylsulfone sulfonamides and use thereof |
| WO2007005785A1 (en) | 2005-07-04 | 2007-01-11 | Dr. Reddy's Laboratories Ltd. | Thiazoles derivatives as ampk activator |
| RU2457207C2 (ru) | 2006-03-24 | 2012-07-27 | Эррэй Биофарма Инк. | Активаторы глюкокиназы |
| ATE495153T1 (de) | 2006-11-09 | 2011-01-15 | Hoffmann La Roche | Arylsulfonylpyrrolidine als 5-ht6-inhibitoren |
| US8513276B2 (en) | 2006-12-22 | 2013-08-20 | Astex Therapeutics Limited | Imidazo[1,2-a]pyridine compounds for use in treating cancer |
| CA2681695A1 (en) | 2007-03-23 | 2008-10-02 | Array Biopharma Inc. | 2-aminopyridine analogs as glucokinase activators |
| EP2573087A1 (en) | 2007-09-21 | 2013-03-27 | Array Biopharma, Inc. | Pyridin-2-yl-amino-1,2,4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus |
| TW200940542A (en) | 2008-01-09 | 2009-10-01 | Array Biopharma Inc | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| WO2009117444A1 (en) | 2008-03-17 | 2009-09-24 | Northeastern University | Inhibitors of fatty acid amide hydrolase and monoacylglycerol lipase for modulation of cannabinoid receptors |
| CN102421800A (zh) | 2009-02-23 | 2012-04-18 | 格兰马克药品股份有限公司 | 结合cd19的人源化抗体及其用途 |
| US20120077401A1 (en) | 2009-03-27 | 2012-03-29 | Tomohiko Kotake | Resin composition for production of clad layer, resin film for production of clad layer utilizing the resin composition, and optical waveguide and optical module each utilizing the resin composition or the resin film |
| UY32582A (es) | 2009-04-28 | 2010-11-30 | Amgen Inc | Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero |
| CN102574822A (zh) | 2009-08-04 | 2012-07-11 | 阿米拉制药公司 | 作为溶血磷脂酸受体拮抗剂的化合物 |
| US8962631B2 (en) | 2010-05-12 | 2015-02-24 | Vertex Pharmaceuticals Incorporated | Compounds useful as inhibitors of ATR kinase |
| CN103270023B (zh) | 2010-09-03 | 2016-11-02 | 福马Tm有限责任公司 | 作为用于治疗疾病诸如癌症的nampt 抑制剂的4-{[(吡啶-3-基-甲基)氨基羰基]氨基}苯-砜衍生物 |
| CA2861491C (en) | 2012-02-13 | 2020-08-25 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | Bispecific chimeric antigen receptors and therapeutic uses thereof |
| US9422252B2 (en) | 2012-05-22 | 2016-08-23 | Autifony Therapeutics Limited | Triazoles as Kv3 inhibitors |
| JP2015524483A (ja) * | 2012-08-09 | 2015-08-24 | ニューロポア セラピーズ，インコーポレイティド | Ｐｉ３−キナーゼシグナリング経路の調節因子としてのアリール及びヘテロアリールで置換されたベンゼン誘導体 |
| US20140044813A1 (en) | 2012-08-09 | 2014-02-13 | Kemin Industries, Inc. | Plant Extracts for Improving Cognitive Health and Function |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| SG11202003879RA (en) * | 2017-10-30 | 2020-05-28 | Neuropore Therapies Inc | Substituted phenyl sulfonyl phenyl triazole thiones and uses thereof |
-
2018
- 2018-10-29 SG SG11202003879RA patent/SG11202003879RA/en unknown
- 2018-10-29 CN CN201880071304.3A patent/CN111372579B/zh not_active Expired - Fee Related
- 2018-10-29 CA CA3080578A patent/CA3080578A1/en active Pending
- 2018-10-29 EP EP18873686.2A patent/EP3703675A4/en not_active Withdrawn
- 2018-10-29 JP JP2020543258A patent/JP7277473B2/ja active Active
- 2018-10-29 KR KR1020207015547A patent/KR102639231B1/ko active Active
- 2018-10-29 BR BR112020008727-0A patent/BR112020008727A2/pt not_active IP Right Cessation
- 2018-10-29 AU AU2018359224A patent/AU2018359224B2/en not_active Ceased
- 2018-10-29 MX MX2020004202A patent/MX2020004202A/es unknown
- 2018-10-29 WO PCT/US2018/058050 patent/WO2019089478A1/en not_active Ceased
-
2019
- 2019-03-27 US US16/366,793 patent/US10501423B2/en active Active
- 2019-10-24 US US16/663,054 patent/US11008294B2/en not_active Expired - Fee Related
-
2020
- 2020-04-16 IL IL274010A patent/IL274010B2/en unknown
-
2021
- 2021-04-06 US US17/223,989 patent/US11708338B2/en active Active
-
2023
- 2023-05-08 JP JP2023076473A patent/JP2023100842A/ja active Pending
- 2023-06-05 US US18/206,005 patent/US20230391734A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7719769B2 (ja) | 抗ウイルスプロドラッグ及びその医薬組成物 | |
| JP2020176156A (ja) | Ｔｏｌｌ様受容体モジュレーターの固体形態 | |
| JP2022547558A5 (https=) | ||
| KR102216381B1 (ko) | 에다라본 및 (+)-2-보르네올의 설하 약학 조성물 | |
| JP2021501202A5 (https=) | ||
| JP2010070566A (ja) | ウイルス性肝炎の処置 | |
| JP2022123032A (ja) | エダラボン医薬組成物 | |
| AU2017326791A1 (en) | Medicinal composition | |
| JP2019526596A5 (https=) | ||
| JP2019510787A5 (https=) | ||
| JP2009522371A5 (https=) | ||
| WO2017140254A1 (zh) | 一种含有jak激酶抑制剂或其可药用盐的药物组合物 | |
| TWI884912B (zh) | 喹啉酮類似物及其鹽、組合物及其使用方法 | |
| JP7617898B2 (ja) | Ｅｙｐ００１を使用した改善された処置 | |
| JP2019501879A5 (https=) | ||
| TW201501730A (zh) | 用於口服投藥之包含非晶型托伐普坦（Ｔｏｌｖａｐｔａｎ）的懸浮液 | |
| US20150064252A1 (en) | Solid dispersion formulation of an antiviral compound | |
| CA3154120A1 (en) | Combination treatment with a p53 reactivator and an inhibitor of an antiapoptotic bcl-2 family protein | |
| WO2012087257A2 (en) | Oral dosage form comprising imatinib and production of said oral dosage form | |
| JP2023526567A5 (https=) | ||
| JP2023533162A5 (https=) | ||
| AU2016331073A1 (en) | Combination therapy regimen for treatment of HCV | |
| KR101282847B1 (ko) | 실로스타졸을 함유하는 고체분산체 및 이를 포함하는 약학 조성물 | |
| JP2017505313A5 (https=) | ||
| JP5932829B2 (ja) | 経口活性ヌクレオチドアナログ又は経口活性ヌクレオチドアナログプロドラッグの高度に安定な組成物 |